G-protein-coupled receptors (GPCR) represent a superfamily of proteins that mediate the function of neurotransmitters and peptide hormones and are involved in viral entry and perception of light, smell, and taste. GPCRs are characterized by the presence of seven transmembrane domains (TMs). We demonstrate here that structural analogs of individual TMs of GPCRs can serve as potent and specific receptor antagonists. Peptides derived from the transmembrane regions of CXCR4 and CCR5 chemokine receptors specifically inhibited receptor signaling and the in vitro replication of human immunodeficiency virus-1 (HIV-1) at concentrations as low as 0.2 M. Similarly, peptides mimicking the TMs of cholecystokinin receptor A, were found to abolish ligand binding and signaling through the receptor. Negative charges positioned at the extracellular termini of peptide antagonists appeared to be important for correct spontaneous insertion of the compounds into the cell membrane and for their activity. Targeting of the specific interactions between transmembrane domains of GPCRs is suggested as a general sequence-based method to disrupt receptor function for application in drug design and for structure-function studies of the receptors.
G-protein-coupled receptors (GPCR)
1 serve as key molecular targets for therapeutic intervention in a host of disease states (1) . Although targeting the external ligand binding sites of GPCRs is the generally accepted strategy in designing antagonists, we have elected to pursue an alternate approach based on the disruption of receptor structure. The amino acid sequences of the members of GPCR superfamily indicate a highly conserved presence of seven hydrophobic domains that are suggested to be transmembrane helices. Transmembrane domains (TMs) are believed to be arranged in a barrel-like structure with a tightly packed core (2) (3) (4) . Recent studies have suggested that GPCRs are composed of several independent folding units (5) (6) (7) (8) (9) (10) (11) (12) (13) . Specifically, coexpression of polypeptides generated by splitting the muscarinic receptor in either the extracellular or the intracellular loops resulted in assembly of the molecules, which exhibited receptor-like function (6, 7) . Fragments of bacteriorhodopsin and rhodopsin also refold into stable helices with partial restoration of protein function (8 -10) . The function of inactive truncated receptors can be rescued by expression of the missing TMs (11) (12) . Finally, a peptide derived from the sixth TM of ␤2-adrenergic receptor was found to inhibit receptor activation and dimerization (13) . Hence, it appears highly probable that TMs of GPCRs interact in a specific way in the assembly of receptor molecules. However, these interactions are unlikely to lead to rigid structures, because flexibility is required to allow for conformational changes during signaling from the cell surface to the intracellular domains. To transmit the signal from one part of the protein to another, the protein needs to have allosteric properties, which implies flexibility in the systems. Together, these observations led us to suggest that targeting intramembrane interactions of GPCRs with designed molecules may allow for specific regulation of receptor function. Thus, it may be possible to create a molecule that can specifically disrupt interaction of transmembrane domains of a particular receptor, which would render the receptor molecule nonfunctional (Fig. 1 ).
EXPERIMENTAL PROCEDURES
Peptide Synthesis-The peptides were synthesized by solid phase peptide synthesis on 432A or 433A Applied Biosystems peptide synthesizers equipped with conductivity monitoring units utilizing Fmoc (N-(9-fluorenyl)methoxycarbonyl) amino acid derivatives. The synthesis was performed with conditional blocking of unreacted amino groups with acetic anhydride for easier purification of the resulting peptides. To overcome aggregation that frequently occurs during the synthesis of hydrophobic peptides and leads to the blockage of the growing peptide chain, NovaSyn TGA resins (Nova Biochem, San Diego, CA) were used. The peptides were purified by reverse phase HPLC on a C18 column in a gradient of 0.05% trifluoroacetic acid, water and acetonitrile. The purity of the peptides was assessed by reverse phase HPLC on C18 and C4 columns, and the structures were confirmed by matrix-assisted laser-desorption ionization time-of-flight mass spectrometry as described (14) .
Assessment of [Ca 2ϩ ] i -The measurements were carried out in Fura-2/AM-treated cells utilizing the Attofluor digital imaging system as described (15) . Stock solution of antagonists (5-10 mM) in dimethyl sulfoxide were diluted in phosphate-buffered saline and added to the cells preloaded with Fura-2/AM. Stimulation with an agonist was carried within seconds after application of an antagonist. CXCR4-positive cells were stimulated with 50 nM stromal cell-derived factor-1 (SDF-1␣; R & D Systems, Minneapolis, MN), and cholecystokinin receptor type A (CCKAR) receptor-mediated response was triggered by 10 nM sulfated CCK-8 (Research Plus Inc., Bayonne, NJ). Subsequent stimulation of the cells with total bovine serum was used as a positive control to verify cell viability and efficient loading with calcium indicator. The minimal concentration required for complete inhibition of signaling was determined by consecutive 2-fold dilutions. Further validation of the mini-* This work was sponsored in part by the NCI, National Institutes of Health under contract with Advanced Bioscience Laboratories. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: (16) . CHO cells expressing CCKAR were obtained as described (15) . Confocal laserscanning microscopy was performed as described (15) . (15) were incubated for 1 h with 10 nM RG-CCK-8 in the presence of various concentrations of the antagonists in phenol red-free medium in a CO 2 incubator. Cells were rinsed three times with medium and observed under the microscope using identical parameters for all concentrations. The images were stored on an optical disc and analyzed with Zeiss LSM software. A minimum of 10 images for each concentration were quantitated.
Inhibition of Rhodamine Green (RG)-CCK-8 Binding to CCKAR-CHO cells stably expressing CCKAR
Anti-HIV-1 Assay-The effects of various TM peptides on HIV-1 replication were determined with CEM-SS cells infected with HIV-1 RF utilizing the XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) cell assay as described previously (27) .
RESULTS AND DISCUSSION
The hypothesis for this research was that an externally added peptide corresponding to one of the putative transmembrane domains of a GPCR was able to disrupt the function of the receptor by interfering with the proper association of the TM domains. To test this hypothesis, we first synthesized peptides corresponding to all seven predicted transmembrane regions of CXC chemokine receptor 4 (CXCR4) (17) and tested their ability to inhibit signaling through the receptor. In the antagonist nomenclature used throughout the paper, the first number after the receptor name refers to the transmembrane domain from which the peptide was derived, and the second number corresponds to the order in which the peptides were synthesized. Potential antagonist activity of the peptides was evaluated by measurement of the inhibition of ligand-induced intracellular Ca 2ϩ release in cells stably expressing CXCR4; SDF-1␣ was used as a ligand at a concentration of 50 nM (K d ϭ 6 nM). In the preliminary screen, peptides corresponding to the second and sixth TMs were found to abolish SDF-1␣-induced signaling through CXCR4 receptor (Table I) .
To further understand the structural requirements for a successful antagonist, structure-activity studies were conducted on the peptides corresponding to the second TM domain of CXCR4 (Table II) . The most potent antagonist thus far obtained, a 24-amino acid residue peptide CXCR4-2-2, completely blocked signal transduction at 0.2 M. Terminal anionic residues appeared to be important for antagonist activity, as elimination of two C-terminal Asp residues (CXCR4-2-1) decreased antagonist potency more than 10-fold, and substitution of Asp residues with positively charged Lys residues (CXCR4-2-3) resulted in a 100-fold decrease in antagonist activity. It is assumed that the charge distribution provides for a proper orientation of the peptides during penetration into the cellular membrane (18) . The results obtained from structure-activity studies with TM2 were applied to other domains and allowed the identification of antagonists derived from all but the first, third, and fifth TM domains (Table III, Fig. 2 ). Peptides derived from the first and the fifth domains imposed significant synthetic difficulties because of aggregation and turned out to be very poorly soluble. In the case of the peptides corresponding to the fourth and seventh TM domain, the positioning of the negatively charged residue at the intracellular terminus of the peptide instead of extracellular terminus or substitution of extracellular Asp with Lys residues abolished the antagonist activity, as had been observed with TM2.
The antagonist potency of CXCR4 -2-2 did not depend on the concentration of SDF-1␣ in a range between 50 and 300 nM. The activity of the compound was tested in U87 cells stably transfected with CXCR4, in HeLa cells that naturally express the receptor, and in HeLa cells stably expressing CXCR4 tagged with green fluorescent protein (25) . All tests produced basically the same results, suggesting that variations in the density of receptor molecules that are within the natural levels of receptor expression do not affect the potency of the antagonist.
The specificity of the TM domain interaction was demonstrated by the fact that all peptides derived from CXCR4 appeared to be selective for that receptor and had no influence on signaling through CCR5, which is the other major chemokine receptor involved in HIV-1 entry. Similarly, a peptide derived from the second TM of CCR5, CCR5-2-1 (Table III) completely abolished agonist (RANTES (regulated on activation normal T cell expressed))-induced CCR5 signaling in U87 cells at 0.5 M but had no effect on signaling of CXCR4.
Interestingly, an equimolar mixture of two peptides CXCR4-6-1 and CXCR4-7-3 was an order of magnitude more potent than the most active of the two and completely inhibited signaling at 1 M concentration (Table III) . Other pairs of peptides failed to show improved potency compared with single components, likely due to nonoptimal combinations and/or nonoptimal structures. Nevertheless, we hypothesized that the synergistic effect produced by a pair of TM derivatives may be a general phenomenon. Consequently, overcoming the entropy factor by linking two TM analogs may result in significantly increased affinity, and thus, appropriate pairs of TM analogs may produce very potent antagonists.
To further generalize the approach, we have synthesized the peptides derived from the TMs of the rat CCKAR. CCKAR was selected for this study because the pharmacology, signaling, and trafficking characteristics of the receptor are well documented (19) . Although CCKAR belongs to the same rhodopsin family of GPCRs as CXCR4, its sequence is only 15% identical to that of CXCR4. The degree of identity in transmembrane parts is only 27%. None of CCKAR-derived peptides served as 
antagonists of chemokine receptors. The abilities of these TM domain peptide analogs to inhibit signaling through the receptor were compared with the ability to prevent agonist binding (Table IV) . Inhibition of signaling was assessed by measurement of the ligand-induced intracellular calcium release in CHO cells stably transfected with rat CCKAR, following administration of the CCK-8 ligand (15) at 10 nM concentration. Inhibition of ligand binding was measured via direct observation of binding of a fluorescently tagged agonist (RG-CCK-8) using quantitative confocal laser-scanning microscopy ( Fig. 3 ) (15) . Peptides derived from the first and the second TMs (CCKAR-1-1 and CCKAR-2-1, respectively (Fig. 4) ) demonstrated comparable potencies in inhibition of ligand binding and signaling, whereas the peptide equivalent to the sixth TM domain, CCKAR-6-1, effectively inhibited signaling but only modestly affected binding of RG-CCK-8 to the cells. The effects of CCKAR-1-1 and CCKAR-2-1 on ligand binding are in agreement with mutational research, suggesting the direct involvement of TM1 and TM2 and the adjacent extracellular regions of GPCRs in agonist binding (21) . Similarly, the intracellular loop connecting TM5 and TM6 of GPCRs is implicated in signaling through interactions with intracellular G-proteins (22) . Thus, it was not unexpected that that the disturbance of receptor structure in the area adjoining TM6 (by CCKAR-6-1) interfered with signaling. However, the fact that the region adjacent to TM6 of CCKAR is less important for ligand binding could not be predicted, taking into consideration the allosteric nature of interactions within the receptor molecule. When the concentration of CCK-8 used to test antisignaling activity of the antagonists was increased from 10 nM to 1 M, the potency of CCKAR-1-1 and CCKAR-2-1 was significantly reduced, and concentrations required to abolish signaling were found to be above the solubility limits of the peptides (100 M) (Table IV) . Thus the natural ligand, CCK-8, appeared to be able to compete out the binding of these two antagonists. However, the antisignaling potency of CCKAR-6 -1 remained unchanged when the agonist concentration was increased 2 orders of magnitude.
The major purpose of the present study was to demonstrate the ability of externally added molecules to compete for the interactions between TM domains of GPCRs. Implicit in this idea was that the GPCR structure, even in properly folded molecules, is flexible enough to be disrupted in this fashion. A similar approach was used to inhibit coupling of GPCRs to intracellular signaling molecules, adenylate cyclase, (23) and G-proteins (24) by peptides corresponding to the intracellular loops of the receptors. Those studies were conducted primarily to provide an understanding of molecular mechanisms of receptor function and could not be applied directly for drug design because of the difficulties in intracellular delivery of the inhibitors. The hydrophobic nature of the transmembrane peptides makes their penetrations into the cell membrane bilayer highly probable, and orientation inside the membrane can be controlled by the addition of charged residues to the extracellular termini. Because the TM2 peptides of CXCR4 were the most effective antagonists identified, we next evaluated the intracellular distribution of these peptides using a fluorescent derivative of CXCR4 -2-2 that was prepared by attachment of a rhodamine B moiety to the extracellular terminus. Rhod-CXCR4-2 was 40 times less potent than the parent CXCR4 -2-2 peptide (see Table II ) but still was able to disrupt receptor function. Localization of the peptide was characterized by confocal laser-scanning microscopy using HeLa cells that stably express a green fluorescent protein-labeled CXCR4 (see Fig. 5 ) 
TABLE III Biological activity of CXCR4 antagonists derived from different transmembrane domains
Antisignaling activity was determined in inhibition of intracellular calcium release induced by 50 nM SDF-1␣ in U87 cells stably expressing CXCR4. Anti-HIV-1 activity was assessed in a cytoprotection assay utilizing CEM-SS cells infected with HIV-1 RF as described (27) . ND, not determined.
Peptide
Concentration required for complete inhibition of signal transduction EC 50 in anti-HIV-1 assay
Positions of the sequences from which the antagonists were derived in the primary structure of CXCR4 (17). Transmembrane domains are underlined, and sequences used for antagonists synthesis are in bold. (25) . Rhod-CXCR4-2 was observed in the cellular membrane within minutes after application, and saturated endosomes and the endoplasmic reticulum were observed within 15 min of incubation. These observations confirm the ability of the new TM domain analogs to insert spontaneously into the cellular membranes, thus enabling interactions with the receptor in all cellular compartments where the receptor molecules are present. After the fluorescent antagonist was removed from the incubation medium, it was retained in the endoplasmic reticulum and in the endosomes for several hours. This observation suggests that the transmembrane peptides may be able to interact with newly synthesized receptor molecules in the endoplasmic reticulum and, thus, have prolonged inhibitory ef- The microscopy was performed as described (15, 25) .
FIG. 6. Anti-HIV efficacy and toxicity of CXCR4-4-2 in cytoprotection assay. CEM-SS cells were infected with RF strain of HIV-1, which causes cell death in the absence of an effective inhibitor (27) . Cell survival was assessed with the help of the XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) assay (27) . Each value represents the mean Ϯ S.E. from at least three experiments performed in triplicates. (15) . Binding studies were conducted in the same cell line utilizing 10 nM RG-CCK-8. Ligand binding was measured by quantitative confocal laser-scanning microscopy as described (15 
fects on the treated cells. It is unlikely however, that the endoplasmic reticulum is the only site of action of the inhibitory peptides, since it is clear from the present data that fully assembled receptor molecules in the plasma membrane are also disrupted. The evidence for this comes from the complete inhibition of signaling within seconds after addition of the peptides (see "Experimental Procedures"). The studies with CXCR4, CCR5, and CCKAR clearly demonstrate the ability of TM domain analogs of GPCRs to disrupt ligand binding and signaling through the receptor. However, our interest was to extend the observation to other biological functions of the receptors. CXCR4 and CCR5 are involved in the fusion of HIV-1 to host cells. Importantly, an indication that TM peptide analogs inhibit CXCR4-dependent functions might be applicable to drug design efforts. Given that CXCR4 represents one of the principal coreceptors for HIV-1 cell entry (reviewed in Ref. 26) and that the TM domain peptides of CXCR4 interfere with receptor functions, we tested TM peptide analogs (corresponding to TM domains 2, 4, 6, or 7) as possible inhibitors of HIV-1 RF replication in a cell-based cytoprotection assay (27) . As shown in Table III , the most potent peptide, CXCR4-4-2, inhibited infection at concentrations below 1 M (IC 50 Ϸ 300 nM) (see also Fig. 6 ), whereas peptides CXCR4-2-2 and CXCR4-7-3 inhibited in the 2-3 M range. None of CCKARderived peptides inhibited HIV-1 infection, and none of the peptides caused cell toxicity at concentrations of up to 100 M (higher concentration could not be tested due to limitations of solubility). These data clearly establish that TM peptide analogs of CXCR4 can inhibit HIV-1 replication, and this approach may be applied to CCR5 and other chemokine receptors that participate in HIV-1 entry into host cells.
We propose that the observed disruption of GPCR function by TM peptide analogs is due to competition of the peptides for interaction between intramembrane helices (Fig. 1) . In the presence of an excess of the peptide the majority of receptor molecules will be inactive because the synthetic peptides occupying the place of the corresponding receptor domain lack the necessary extramembrane components. It should be noted that the antagonistic potency of the peptides may depend not only on the interaction with the target receptor but also on the efficiency of membrane insertion of externally added molecules. Thus, the poor activity of some peptides may be partially attributed to their weak ability to enter the plasma membrane. Indeed, different transmembrane domains of CCKAR were previously shown to have varying abilities to insert into membranes (28) . The detailed characterization of the competence of different TM analogs to insert into the membranes and interact with each other in a specific manner as well as the participation of discrete residues of peptides to interact with receptor domains is ongoing in our laboratory. We suggest that information from these studies can be utilized to construct more efficient TM inhibitors. Screening of combinatorial libraries of peptides can also assist in selection of more potent antagonists. Peptidomimetics have been successfully applied for construction of analogs of helical peptides and, thus, can be used to obtain antagonists demonstrating enhanced pharmacokinetic properties (29) .
In conclusion, we suggest that peptides, peptidomimetics, or even small molecules can be utilized as novel classes of antagonists to target the TM regions of GPCRs and disrupt receptor function. TM antagonists would not only be useful in the development of new drug candidates but would also facilitate the study of GPCR function and three-dimensional structures. In addition, effective antagonists might be designed based solely on amino acid sequences, and thus, the approach also should be useful for targeting orphan receptors. Finally, the TM-targeting approach need not be restricted to GPCR molecules but might also be applied to multimembrane-spanning proteins of other classes, since specific interactions between TM domains are vitally important for the functions of a diverse set of surface proteins.
